Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03302325 · ClinicalTrials.gov registry record
Circulating Tumor DNA As Liquid Biopsy in Patients with Stage IV Solid Tumors, a Feasibility Study At MUSC HCC
A clinical trial, sponsored by Medical University of South Carolina.
- Completed
- Registry status
- 20
- Enrollment target
NCT03302325: Completed study, sponsored by Medical University of South Carolina.
NCT03302325 is a clinical trial that has completed, run by Medical University of South Carolina. The registered enrollment target is 20 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03302325 has completed, sponsored by Medical University of South Carolina.
- COMPLETED
- Registry status
- 20 participants
- Enrollment target
Study Summary
1. To demonstrate the ability to detect specific cancer mutations in ctDNA isolated from plasma of stage IV cancer patients at HCC. 2. To compare, in each patient, ctDNA longitudinal samples through treatment, and when available, with those of primary tumor and metastasis.
Interventions
- PROCEDURE research blood draws
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2017-10-12 |
| Est. Completion | 2020-01-06 |
What the finished NCT03302325 record still lists
NCT03302325 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 20 participants, a relatively small participant target.
The record links to 0 conditions, and to 1 intervention - of which research blood draws is the first listed.
NCT03302325 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03302325 about?
NCT03302325 is a clinical study titled "Circulating Tumor DNA As Liquid Biopsy in Patients with Stage IV Solid Tumors, a Feasibility Study At MUSC HCC". 1. To demonstrate the ability to detect specific cancer mutations in ctDNA isolated from plasma of stage IV cancer patients at HCC. 2. To compare, in each patient, ctDNA longitudinal samples through treatment, and when available, with those of primary tumor and metastasis.
What is the current status of trial NCT03302325?
This trial is currently completed. The enrollment target is 20 participants. The study started on 2017-10-12. Estimated completion is 2020-01-06.
What interventions are being tested in trial NCT03302325?
The interventions under investigation include: research blood draws (PROCEDURE).
Who is sponsoring clinical trial NCT03302325?
This trial is sponsored by Medical University of South Carolina, which has 755 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00573339 · 20 participants
Cardiac Magnetic Resonance Imaging (MRI) Normal Reference Control Group Testing
- NCT00692939 · 20 participants · Phase 1
Autologous Stem Cell Transplantation for Crohn's Disease
- NCT00967785 · 20 participants · Phase 1
A Phase I Study of Mozobil in the Treatment of Patients With WHIMS
- NCT01406691 · 20 participants · Phase 4
Light Flashes to Treat Delayed Sleep Phase Disorder (DSPD)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI